Earnings Per Share (GAAP)
$-0.27
vs $-0.17 est. (narrower loss, 19.9%)
Revenue
$0
vs $9.4M est.
Analyst support holds firm. The Street maintains a bullish stance with eight of nine analysts rating shares Buy or better, unchanged from the prior two months. Trading volume of 346,878 shares came in below recent averages as the stock held steady at $2.12. Shares trade 57% below the 52-week high of $4.94 set earlier in the fiscal year.
What to Watch: The company’s next clinical data readout will determine whether the narrowing loss trajectory can continue without revenue generation. Monitor cash runway disclosures in the 10-K filing due within 60 days of quarter-end.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.